The Company is engaged in the research, development and commercialisation of novel drugs for the treatment of central nervous system disorders. Amarin produces and sells Vasecepa - A prescription Omega 3 pill. Sales are $700M annually expected to rise to $2B over the next year.
April 4, 2020
Amarin shares sank 70% after a federal judge invalidated several patents pertaining to the drug. That means generic competitors may enter the market and take a piece of the pie sooner rather than later.